Literature DB >> 16430636

Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation.

Karl-Erik Andersson1, John P Mulhall, Michael G Wyllie.   

Abstract

OBJECTIVE: To describe the relationship between the pharmacokinetic and pharmacodynamic properties of dapoxetine, a drug specifically developed for treating premature ejaculation (PE).
METHODS: Data from various stages of the clinical development programme were analysed using validated methods for assessing ejaculatory latency. The clinical characteristics were then compared with the pharmacokinetic profile, determined from measured plasma drug concentrations.
RESULTS: Pharmacodynamic and pharmacokinetic measurements confirm that 'on demand' dapoxetine has a rapid onset of action and is rapidly cleared after sexual intercourse.
CONCLUSION: Dapoxetine may represent the first of a new category of selective serotonin transport inhibitors. Although dapoxetine has pharmacological similarities to other selective serotonin transport inhibitors, its efficacy after acute administration sets it apart and suggests a different mode of action. Its physicochemical and pharmacokinetic properties and its clinical efficacy make dapoxetine suitable for on-demand treatment of PE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430636     DOI: 10.1111/j.1464-410X.2006.05911.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

Review 1.  A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation.

Authors:  Kate Hutchinson; Kelly Cruickshank; Kevan Wylie
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

Review 2.  Current therapeutic strategies for premature ejaculation and future perspectives.

Authors:  Zhong-Cheng Xin; Yi-Chen Zhu; Yi-Ming Yuan; Wan-Shou Cui; Zhe Jin; Wei-Ren Li; Tao Liu
Journal:  Asian J Androl       Date:  2011-05-02       Impact factor: 3.285

Review 3.  Current and emerging treatment options for premature ejaculation.

Authors:  Murat Gul; Kadir Bocu; Ege Can Serefoglu
Journal:  Nat Rev Urol       Date:  2022-08-25       Impact factor: 16.430

4.  Management of premature ejaculation: a clinical guideline from the Italian Society of Andrology and Sexual Medicine (SIAMS).

Authors:  A Sansone; A Aversa; G Corona; A D Fisher; A M Isidori; S La Vignera; E Limoncin; M Maggi; M Merico; E A Jannini
Journal:  J Endocrinol Invest       Date:  2020-10-30       Impact factor: 4.256

Review 5.  Recent advances in the treatment of premature ejaculation.

Authors:  Kate D Linton; Kevan R Wylie
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

6.  Zein-alpha lipoic acid-loaded nanoparticles to enhance the oral bioavailability of dapoxetine: optimization and clinical pharmacokinetic evaluation.

Authors:  Khalid M El-Say; Osama Aa Ahmed; Amir I Mohamed; Martin K Safo; Abdelsattar M Omar
Journal:  Int J Nanomedicine       Date:  2019-09-12

7.  Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation.

Authors:  Ej McCarty; Ww Dinsmore
Journal:  Core Evid       Date:  2012-01-19

8.  Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study.

Authors:  Hyun Jun Park; Nam Cheol Park; Tae Nam Kim; Seung Ryong Baek; Kyung Min Lee; Sangmin Choe
Journal:  Sex Med       Date:  2017-04-05       Impact factor: 2.491

9.  Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation.

Authors:  Muammer Kendirci; Emad Salem; Wayne Jg Hellstrom
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

10.  Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation.

Authors:  Abdulmuttalip Simsek; Sinan Levent Kirecci; Onur Kucuktopcu; Faruk Ozgor; Mehmet Fatih Akbulut; Omer Sarilar; Unsal Ozkuvanci; Zafer Gokhan Gurbuz
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.